Anixa Biosciences and the Cleveland Clinic have filed an investigational new drug application for a breast cancer vaccine with the U.S. Food and Drug Administration. The vaccine technology was developed by researchers at the Cleveland Clinic. Funding from the U.S. Department of Defense is expected to enable completion of two Phase 1 clinical trials, according to a press release. The vaccine, for which Anixa holds an exclusive worldwide license, targets certain proteins produced by a…
You must be logged in to read/download the full post.
The post Anixa Biosciences, Cleveland Clinic Developing Breast Cancer Vaccine appeared first on BioNewsFeeds.